Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. - Wikidata - awgldk - TriplyDB

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

http://www.wikidata.org/entity/Q33668068

about

Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Down-regulation of LRRK2 in control and DAT transfected HEK cells increases manganese-induced oxidative stress and cell toxicity Manganism in the 21st century: the Hanninen lecture Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers The role of biomarkers and imaging in Parkinson's disease.Neuroimaging in pre-motor Parkinson's disease Neuroimaging: current role in detecting pre-motor Parkinson's disease.Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease.Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers.Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications Imaging in Parkinson's disease: time to look below the neck.Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier.LRRK2 in Parkinson's disease: genetic and clinical studies from patients.Milestones in neuroimaging.Moving forward: advances in the treatment of movement disorders with deep brain stimulation.Biomarkers for trials of neuroprotection in Parkinson's disease.Biomarkers of Parkinson's disease: current status and future perspectives.Functional neuroimaging in Parkinson's disease.Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.Neuroimaging in the early diagnosis of neurodegenerative disease.Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in mice Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.Compensatory striatal-cerebellar connectivity in mild-moderate Parkinson's disease.Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system.CSF Nrf2 and HSPA8 in Parkinson's disease patients with and without LRRK2 gene mutations.Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET.

P2860

Q24293070-07DFD478-CCC2-4DCA-890C-77E33A9F1B29 Q24339471-D3808BF5-F1CD-49E4-8764-F80D529854EF Q27015750-22A149CF-5D46-4E39-BAB7-CC1B6340BC2D Q28589899-2CC0203E-6E65-4054-BFA0-71D7DAF4B944 Q30524899-F277CB1D-53D0-4959-91D4-BEA312E95F01 Q30525550-83190F56-1501-412D-A656-27AEEEB45A55 Q31041660-3E352A4B-D3C8-4913-84FE-0912DDC2FF7B Q33676222-0C132B17-77E9-4CBB-93DD-1438F779E709 Q34234625-6E1279C4-954F-436A-8B62-283DEC6DBDBA Q34242682-51DE4600-2E65-41D6-9D6A-9775DBC46D10 Q34267681-A1151E6E-B557-427C-BC84-D2A9A70080C1 Q35059247-E604D2BB-35A3-4A79-9681-FA81A9545F7F Q35106295-6ED6AB5F-C337-4BEA-BF70-ADAE682E8308 Q35148581-FC7A7550-8F48-425F-90BE-E425E913DD27 Q35533959-2D9922B6-591D-4686-B002-D7668BEB30AE Q36553302-30E9A48D-11DE-4A89-B5A6-EF841D48B0D2 Q36972794-3257CDFF-B723-4724-9618-8DED240E1C2C Q37608624-53B558C3-92A5-4304-BC57-5E438EE155FD Q37882576-8F1EDD4C-C41C-4A6A-91A1-ACCC98F986F9 Q37956311-4B0B62CD-F109-4618-AE3B-063AC931C628 Q38038544-2AB1AC24-AE2E-46E5-B98A-2671D8C5A3AC Q38043841-35617606-A28B-4872-B2AF-FDEA50F58113 Q38088371-6DCDC84B-C26C-43A4-ACEC-F12244CFEE19 Q38881337-BEF3B4F2-76AE-4F4D-97AF-707295B7A682 Q42043633-3FBF849E-6661-4901-91B9-E804FF32116B Q42268862-C50622C8-C641-4E91-A8E3-49A548F3869F Q42353561-BDFD5A4E-2677-468A-A4F8-3633D6AEAC18 Q42495787-656AA928-4D3E-4F2F-8525-A3F1FC14D731 Q43143708-18DB138F-83C5-4036-88CD-1EC5FA3D9F41 Q44060284-0DE2A7F3-C5A1-45DA-9B76-85CE5BECA2D7 Q47907932-CDE0C27F-AF6B-4217-9494-276098D6212A Q49886566-CF3348BD-0284-4E89-9C95-B8C5A3114CF4 Q53386963-5005624C-7C62-41A3-91EC-93B5E718E574 Q55037516-418EA5B9-6FAD-4399-928F-427E96F8F2D9 Q55287139-BEE0CE5B-C0C5-4846-9ABF-E0B58BE5932A

P2860

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

http://www.wikidata.org/entity/Q33668068

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@ast

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@en

type

label

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@ast

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@en

prefLabel

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@ast

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@en

P1433

Q33668068-4271098E-8572-4FBB-8F00-F7134E905BDF

P1476

Q33668068-740507F5-9F21-4C2B-9962-52D2724A1B2F

P2093

Q33668068-0D85F5D7-C8A8-4F45-BD39-6E43D22C35B5

Q33668068-17FD7871-D6AF-4F0B-B56A-AE292B30B7ED

Q33668068-19086A89-5608-4DBE-BC7C-9B167E5F8D2B

Q33668068-32B276E8-FC26-41B8-91E1-509A025FA071

Q33668068-7F87AC39-C730-4BDE-AF9B-786D09424C52

Q33668068-C5E08604-071D-4806-BBF7-158A49EC4C83

Q33668068-DF774B11-7ED0-4B51-9D64-93F58AE99FE9

Q33668068-FCACC084-EE96-42C7-B209-675E3F828281

Q33668068-FE137F7E-230F-4F91-85B2-74AFEE8E28AE

Q33668068-FFD41038-4A24-48BD-BDEB-3EBBBC60A6F8

P2860

Q33668068-13CF90AD-3A34-4D27-B35A-2559D260D420

Q33668068-50F90E3D-5F19-42A9-9B0A-82B67A2F19C6

Q33668068-52C98AB0-7B97-4E9C-BD4D-8ED084EF56E3

Q33668068-6B1D910B-E952-4878-807B-32937843E7F4

Q33668068-7F5124F1-B344-4C7C-8240-AD76BAF4EF76

Q33668068-976B8E39-D1B4-47F5-9244-6EEC6140CD11

Q33668068-9DA7A235-8A04-44F0-9878-5E5A9C34DE71

Q33668068-A376F3CE-97DA-4740-9B90-7CD7A5E74B52

Q33668068-D6851490-F4F9-4C78-8179-6ED302A83C69

Q33668068-D872E2F9-E85B-4B61-B201-AA7BB8D32A96

P304

Q33668068-DEA002EE-C120-420A-B820-741A1BF52487

P31

Q33668068-785C4ECB-52A8-4ECC-98D3-707E5927239A

P356

Q33668068-F5A005FC-E305-4DEA-999E-09B287ED4EC7

P407

Q33668068-85334324-6037-421C-B1C5-EEB32B340963

P433

Q33668068-A359E88A-F796-4B8C-9F6E-B1CE4F076E11

P478

Q33668068-E136E2F0-D74C-4D29-BA8B-C54D6FAE047E

P50

Q33668068-515EC7A2-155B-4B67-B3A5-26775D8EB80A

P577

Q33668068-F1FB6A9C-368F-4F53-B6A9-7D72BFA31A44

P5875

Q33668068-209C0C44-1EC8-4AE8-8142-1F4EC784C41C

P698

Q33668068-EDF89379-D19A-4256-A6E4-34147EB641BC

P921

Q33668068-70A58C6F-A38E-47DF-BF6C-BF00B494AA20

P932

Q33668068-3DE53B61-1BDF-414D-85EC-9025CF0854F1

P356

01.WNL.0000335973.66333.58

P1433

P1476

Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study.

@en

P2093

A J Stoessl

http://www.w3.org/2001/XMLSchema#string

A Strongosky

http://www.w3.org/2001/XMLSchema#string

E Mak

http://www.w3.org/2001/XMLSchema#string

J McKenzie

http://www.w3.org/2001/XMLSchema#string

M J Farrer

http://www.w3.org/2001/XMLSchema#string

M Schulzer

http://www.w3.org/2001/XMLSchema#string

R Nandhagopal

http://www.w3.org/2001/XMLSchema#string

S McCormick

http://www.w3.org/2001/XMLSchema#string

T J Ruth

http://www.w3.org/2001/XMLSchema#string

V Sossi

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

PARK8 LRRK2 parkinsonism

Criteria for diagnosing Parkinson's disease.

Distribution volume ratios without blood sampling from graphical analysis of PET data.

[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studies

Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Nigrostriatal function in humans studied with positron emission tomography.

MRI-PET registration with automated algorithm.

Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.

P304

1790-1795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/01.WNL.0000335973.66333.58

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Zbigniew K Wszolek

P577

2008-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23493418

http://www.w3.org/2001/XMLSchema#string

P698

19029519

http://www.w3.org/2001/XMLSchema#string

P921

P932

2824449

http://www.w3.org/2001/XMLSchema#string